Patents Represented by Attorney, Agent or Law Firm Brenda Herschbach Jarrell
  • Patent number: 6503882
    Abstract: A method for increasing immune responses of a human patient infected with HIV, involving contacting the T-cells, in vitro or in vivo, with an organic compound at a concentration effective to cause T-cell proliferation, but below an amount that causes detectable cytotoxicity.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: January 7, 2003
    Assignee: Trustees of Tufts College
    Inventors: Brigitte T. Huber, Tracy Schmitz, Robert Underwood
  • Patent number: 6486311
    Abstract: Peanuts are a common cause of food hypersensitivity reactions. The sera of 10 patients who had atopic dermatitis and a positive double-blind placebo-controlled food challenge to peanut were used to investigate the major allergens of peanut. Crude Florunner extracts were fractionated by anion-exchange chromatography using a step gradient (limit buffer, 0.05M BisTris/1.5M NaCl). A protein peak (OD 280) which eluted at 10% NaCl and demonstrated intense IgE-binding was further analyzed by two-dimensional SDS-PAGE/immunoblot analysis. The majority of this fraction is a protein which has a molecular weight of 17 kD and a pI of 5.2. Sequencing data from the N-terminus revealed the following initial 9 amino acids: (*)-Q-Q-(*)-E-L-Q-D-L. Based on IgE-binding activity and no known amino acid sequence identity to other allergens, this allergen is designated Ara h II. Ara h II may be used to detect and quantify peanut allergens in foodstuffs.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: November 26, 2002
    Assignees: Mt. Sinai School of Medicine, University of Arkansas
    Inventors: A. Wesley Burks, Jr., J. Steven Stanley, Gael Cockrell, Nina E. King, Hugh A. Sampson, Ricki M. Helm, Gary A. Bannon
  • Patent number: 6448443
    Abstract: The present invention provides complex compounds reminiscent of natural products and libraries thereof, as well as methods for their production. The inventive compounds and libraries of compounds are reminiscent of natural products in that they contain one or more stereocenters, and a high density and diversity of functionality. In general, the inventive libraries are synthesized from diversifiable scaffold structures, which are synthesized from readily available or easily synthesizable template structures. In certain embodiments, the inventive compounds and libraries are generated from diversifiable scaffolds synthesized from a shikimic acid based epoxyol template. In other embodiments, the inventive compounds and libraries are generated from diversifiable scaffolds synthesized from the pyridine-based template isonicotinamide. The present invention also provides a novel ortho-nitrobenzyl photolinker and a method for its synthesis.
    Type: Grant
    Filed: July 25, 1998
    Date of Patent: September 10, 2002
    Assignee: President and Fellows of Harvard College
    Inventors: Stuart L. Schreiber, Matthew D. Shair, Derek S. Tan, Michael A. Foley, Brent R. Stockwell
  • Patent number: 6441142
    Abstract: Peanuts are a common cause of food hypersensitivity reactions. The sera of 10 patients who had atopic dermatitis and a positive double-blind placebo-controlled food challenge to peanut were used to investigate the major allergens of peanut. Crude Florunner extracts were fractionated by anion-exchange chromatography using a step gradient (limit buffer, 0.05M BisTris/1.5M NaCl). One hundred microliters of each 2.0 ml fraction was dot-blotted onto nitrocellulose paper and IgE-binding activity assessed using the serum pool to select allergen-containing fractions. A protein peak (OD 280) which eluted at 10% NaCl and demonstrated intense IgE-binding was further analyzed by two-dimensional SDS-PAGE/immunoblot analysis. The majority of this fraction is a protein which has a molecular weight of 17 kD and a pI of 5.2. Sequencing data from the N-terminus revealed the following initial 9 amino acids: (*)-Q-Q-(*)-E-L-Q-D-L.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: August 27, 2002
    Assignee: University of Arkansas
    Inventors: A. Wesley Burks, Jr., Ricki M. Helm
  • Patent number: 6383773
    Abstract: The present invention provides a biological system for expanding the dethiazolidine ring of penicillins into the dehydrothiazine ring of cephalosporins or cephalosporin precursors. In particular, the invention defines reaction conditions under which expandase enzyme can convert penicillin substrates other than penicillin N into cephalosporins. The invention therefore provides a relatively inexpensive, uncomplicated, and environmentally friendly biological system for cephalosporin production from penicillins, which system can replace the synthetic chemical approaches currently utilized. In particular, the invention provides a system for producing DOAG and/or DAG, which can be enzymatically converted into 7-ADCA and 7-ADAC, which, in turn, can be enzymatically or chemically converted into valuable cephalosporins of commerce.
    Type: Grant
    Filed: April 22, 1999
    Date of Patent: May 7, 2002
    Assignee: Massachusetts Institute of Technology
    Inventors: Arnold L. Demain, Hiroshi Cho, Jacqueline M. Piret, Josè L. Adrio, Maria-Josefa E. Fernandez, Marco A. Bàez-Vàsquez, Gilberto Hintermann
  • Patent number: 6358712
    Abstract: The present invention provides an improved system for linking nucleic acids to one another. In particular, the present invention provides techniques for producing DNA product molecules that may be easily and directly ligated to recipient molecules. The product molecules need not be cleaved with restriction enzymes in order to undergo such ligation. In preferred embodiments of the invention, the DNA product molecules are produced through iterative DNA synthesis reactions, so that the product molecules are amplified products. The invention further provides methods for directed ligation of product molecules (i.e., for selective ligation of certain molecules within a collection of molecules), and also for methods of exon shuffling, in which multiple different product molecules are produced in a single ligation reaction. Preferred embodiments of the invention involve ligation of product molecules encoding functional protein domains, particularly domains naturally found in conserved gene families.
    Type: Grant
    Filed: January 5, 1999
    Date of Patent: March 19, 2002
    Assignee: Trustee of Boston University
    Inventors: Kevin A. Jarrell, Vincent W. Coljee, William Donahue, Svetlana Mikheeva
  • Patent number: 6355434
    Abstract: The present invention provides identification of sequence polymorphisms in the 5-lipoxygenase gene that are present in general and asthmatic populations. The invention provides methods associated with correlating such polymorphisms with asthmatic phenotype and responsiveness to therapy. In particular, the invention demonstrates that individuals with reduced 5-lipoxygenase expression (or activity) are less responsive to treatment with 5-lipoxygenase inhibiters.
    Type: Grant
    Filed: July 17, 2000
    Date of Patent: March 12, 2002
    Assignee: Brigham & Women's Hospital
    Inventors: Jeffrey M. Drazen, Kwang-Ho In, Koichiro Asano, David Beier, James Grobholz
  • Patent number: 6344475
    Abstract: This invention provides the methodology and agents for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention of proteins. Thus, the methods and agents of the present invention provide for the release of normally retained proteins from the endoplasmic reticulum. The present invention is particuarly useful for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention or degradation of mis-assembled or mis-folded proteins.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: February 5, 2002
    Assignee: Yale University
    Inventors: Michael J. Caplan, Marie E. Egan
  • Patent number: 6326193
    Abstract: The invention includes an expression vector engineered to produce double-stranded RNA (dsRNA) within a pest to be controlled. The dsRNA inhibits expression of at least one gene within the pest, wherein inhibition of the gene exerts a deleterious effect upon the pest. For example, inhibition of the gene can lead to cessation of feeding, growth, or development and can cause death of the pest. In a preferred embodiment of the invention the expression vector is a recombinant baculovirus that transcribes sense and antisense RNA under the control of the baculovirus IE-1 promoter and hr5 enhancer. Preferred genes to be inhibited include essential genes, genes involved in neurotransmission, and genes that are targets for conventional pesticides. The invention discloses baculovirus transfer plasmids useful for producing the recombinant baculovirus. The invention further discloses methods and formulations involving the expression vector.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: December 4, 2001
    Assignee: Cambria Biosciences, LLC
    Inventors: Leo Liu, Scott Chouinard, James Velema
  • Patent number: 6299875
    Abstract: Compositions are administered to block IgE binding to receptors and ultimately displace native IgE from mast cells and related cell types, to prevent the activation of these cells during an allergic response. The compositions consist of a pharmaceutically acceptable carrier for systemic or local administration and an amount of compound binding specifically to the Fc&egr;RI IgE binding sites, and more preferably, Fc&egr;RI and Fc&egr;RII IgE binding sites, to prevent activation and degranulation of mast cells in response to exposure to allergens. The compounds can consist of IgE molecules and fragments and modifications thereof, such as IgE fragments, humanized or single chain IgE antibodies or fragments thereof, IgE with a modified Fab, non-crosslinkable IgE, or peptidomimetics which bind to the same site on the receptor as the IgE, jointly referred to herein as “IgE fragments” unless otherwise stated.
    Type: Grant
    Filed: June 4, 1998
    Date of Patent: October 9, 2001
    Assignee: Panacea Pharmaceuticals, LLC
    Inventors: Michael Caplan, Howard Sosin
  • Patent number: 6221676
    Abstract: An isolated nucleotide sequence encoding human leukotriene C4 synthase or variants of human leukotriene C4 synthase polypeptide, is provided. One embodiment is an isolated DNA sequence (SEQ ID NO.:1) encoding a human leukotriene C4 synthase polypeptide, that has three hydrophobic transmembrane domains. Also described are recombinant cells and plasmids containing the foregoing isolated DNA, preferably linked to a promoter. Isolated leukotriene C4 synthase is provided, having at least three hydrophobic transmembrane domains (SEQ ID NO.:2). Portions of the foregoing isolated human leukotriene C4 synthase polypeptide are also described. Antibodies with selective binding specificity for the polypeptides of the invention also are provided as well as a sensitive method for assay of human leukotriene C4. Methods for producing leukotriene C4 synthase as well as methods for testing for modulators of leukotriene C4 synthase activity are also described.
    Type: Grant
    Filed: December 8, 1997
    Date of Patent: April 24, 2001
    Assignee: Brigham and Women's Hospital
    Inventors: Bing K. Lam, John F. Penrose, K. Frank Austen
  • Patent number: 6207704
    Abstract: Novel compounds that are anti-angiogenic or immunosuppressive are described. Also described are methods for determining if an animal is at risk for a disease involving abnormal angiogenesis or an immune reaction resulting in pathology comprising evaluating an aspect of MetAP2 metabolism or structure; methods for identifying agents that are anti-angiogenic or immunosuppressive comprising evaluating the effect of the agent on an aspect of MetAP2 metabolism; methods for treating a cell having an abnormality in metabolism or structure of MetAP2; and methods for treating abnormal angiogenesis or an immune reaction which results in pathology in an animal. Pharmaceutical compositions are also provided.
    Type: Grant
    Filed: June 8, 1998
    Date of Patent: March 27, 2001
    Assignee: Massachusetts Institute of Technology
    Inventors: Jun O. Liu, Eric C. Griffith, Zhuang Su
  • Patent number: 5962286
    Abstract: Strains of Aureobasidium pullulans (de bary) Arnaud can be used for the commercial production of gluconic acid by fermentation in aqueous liquid containing sugar, which in continuous culture from glucose form greater than or equal to 90% and greater than or equal to 90% molar selectivity. The process is conducted with an Fe and Mn optimized medium with a nitrogen-independent (N-independent) ion concentration. The iron (Fe) concentration with 3 g/l NH.sub.4 Cl is greater than or equal to 0.5 mM, and the manganese (Mn) concentration with 3 g/l NH.sub.4 Cl is greater than or equal to about 0.5 mM manganese (Mn). The pH is regulated between about 4.5 and about 8, in particular at 6.5-7, and the temperature between 24 and 32.degree. C., in particular at 29-30.degree. C. Particularly successful strains are Aureobasidium pullulans (de bary) Arnaud with the registration numbers DSM 7085, DSM 7086, DSM 7087, and DSM 7088.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: October 5, 1999
    Inventors: Savas Anastassiadis, Alexander Aivasidis, Christian Wandrey
  • Patent number: 5917195
    Abstract: A structure of periodically varying density is provided, that acts as a phonon resonator for phonons capable of participating in phonon-electron interactions. Specifically, a phonon resonator that is resonant for phonons of appropriate momentum to participate in indirect radiative transitions and/or inter zone intervalley scattering events is provided. Preferably, the structure is an isotope superlattice, most preferably of silicon. The structure of the present invention has improved optical, electrical, and/or heat transfer properties. A method of preparing a the structure of the present invention is also provided.
    Type: Grant
    Filed: February 17, 1995
    Date of Patent: June 29, 1999
    Assignee: B.A. Painter, III
    Inventor: Thomas G. Brown
  • Patent number: 5877009
    Abstract: The present invention provides isolated apolipoprotein transcription factors and gene regulatory elements. The invention also provides methods of modulating apolipoprotein gene expression by interfering with interactions between apolipoprotein transcription factors and their cognate regulatory elements and/or by interfering with protein-protein interactions between or among apolipoprotein transcription factors or between an apolipoprotein transcription factor and the transcription machinery. This invention has application in the treatment of disorders relating to lipid metabolism (e.g. atherosclerosis, hypertriglyceridemia, etc.).
    Type: Grant
    Filed: December 28, 1993
    Date of Patent: March 2, 1999
    Assignee: Trustees of Boston University
    Inventors: Vassilis I. Zannis, Christos Cladaras